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The SDHD gene (subunit D of succinate dehydrogenase) has been shown to be involved in the generation of paragangliomas and
pheochromocytomas. Loss of heterozygosity of the normal allele is necessary for tumor transformation of the affected cells. As
complete SdhD deletion is lethal, we have generated mouse models carrying a “floxed” SdhD allele and either an inducible
(SDHD-ESR strain) or a catecholaminergic tissue-specific (TH-SDHD strain) CRE recombinase. Ablation of both SdhD alleles in
adult SDHD-ESR mice did not result in generation of paragangliomas or pheochromocytomas. In contrast, carotid bodies from
these animals showed smaller volume than controls. In accord with these observations, the TH-SDHD mice had decreased cell
numbers in the adrenal medulla, carotid body, and superior cervical ganglion. They also manifested inhibited postnatal matura-
tion of mesencephalic dopaminergic neurons and progressive cell loss during the first year of life. These alterations were particu-
larly intense in the substantia nigra, the most affected neuronal population in Parkinson’s disease. Unexpectedly, TH neurons
in the locus coeruleus and group A13, also lacking the SdhD gene, were unaltered. These data indicate that complete loss of SdhD
is not sufficient to induce tumorigenesis in mice. They suggest that substantia nigra neurons are more susceptible to mitochon-
drial damage than other catecholaminergic cells, particularly during a critical postnatal maturation period.
Mitochondrial complex II (MCII; succinate-ubiquinone oxi-doreductase [Sdh]) is composed of four nucleus-encoded
subunits (A, B, C, and D) that couple oxidation of succinate to
fumarate in the Krebs cycle to the mitochondrial electron trans-
port chain (ETC). This is achieved by transferring electrons from
the flavinmoiety in SdhA to iron-sulfur clusters in SdhB and then
to ubiquinone bound to SdhC and SdhD. These last subunits also
serve to anchor the whole complex to the inner mitochondrial
membrane (21, 58). Genetic defects in MCII generate several hu-
man diseases (for a review, see reference 43). Mutations in Sdh
subunits, particularly in SdhB, -C, and -D, commonly produce
familial pheochromocytomas and paragangliomas. These are
highly vascularized, mostly benign, tumors occurring in the adre-
nal gland and the carotid body (CB) but also in other cat-
echolaminergic neural-crest-derived tissues (3, 34). Cell lines with
reductions in Sdh activity caused by mutations in SdhB or SdhC
show signs of oxidative damage and apoptosis, although mutant
cells escaping apoptosis may undergo tumor transformation (19,
24, 25). Indeed, spontaneous loss of heterozygosity (LOH) in
adult humans carrying a mutant SDHD allele (SDHD/) can
induce tumorigenesis in the affected cells (5, 6). The tumorigenic
potential ofMCIImutations has been suggested to derive from the
accumulation of succinate, which inhibits -ketoglutarate-de-
pendent prolyl hydroxylases (PHDs), thus causing a “pseudohy-
poxic” condition with hypoxia-inducible factor 1 (HIF-1) sta-
bilization and nuclear translocation in normoxia (8, 41, 51). This
would result in constitutive activation of genes that favor tumor
growth (42). Impairment of electron transfer from reduced flavin
to ubiquinone in SdhC- or SdhD-deficient cells can lead to exces-
sive production of reactive oxygen species (ROS) (21, 58). Hence,
it has also been proposed that oxidative stress could contribute to
tumorigenesis due to DNA damage (25) and/or ROS-dependent
HIF-1 upregulation (12, 19).
The molecular effects of MCII dysfunction in vivo are practi-
cally unknown, as bi-allelic genetic deletion of any of the Sdh
genes tested so far (SdhB and SdhD knockouts) produce embry-
onic lethality (4, 31, 40). Moreover, heterozygous SdhD-deficient
mice up to 2 years of age do not present tumors or any other
obvious pathology, although they seem to have subtle CB altera-
tions (4, 40). The objective of the current research was to develop
an SdhD conditional knockout mutant mouse that could recapit-
ulate the LOHrequired in humans for tumor formation in periph-
eral paraganglia. To this end,we generatedmousemodels carrying
a “floxed” SdhD allele and either a ubiquitously expressed tamox-
ifen-inducible CRE recombinase (SDHD-ESR mouse) or a CRE
recombinase under the control of the tyrosine hydroxylase (TH)
promoter (TH-SDHDmouse), the rate-limiting enzyme for cate-
cholamine synthesis. Our goals were to ascertain whether ablation
of the SdhD gene induces either cell death or tumor transforma-
tion in vivo and to compare the vulnerability of peripheral and
central catecholaminergic neurons to primary mitochondrial
ETC dysfunction. In this regard, we were particularly interested in
the analysis of dopaminergic neurons in the substantia nigra pars
compacta (SNpc), the most important neuronal population af-
fected in Parkinson’s disease (PD), as mitochondrial impairment
has long been associated with the pathogenesis of this neurode-
generative disorder (14, 15, 48). Herein, we report that deletion of
the SdhD floxed allele in adult heterozygous (SdhDflox/) mice did
not result in generation of paragangliomas or pheochromocyto-
mas. Moreover, germ line deletion of the SdhD allele restricted to
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TH tissues did not induce tumor transformation of the cat-
echolaminergic cells, despite the fact that the animals survived for
up to a year. In contrast, these last mice showed a selective degen-
eration of catecholaminergic cells in the peripheral and central
nervous system and a pronounced and progressive parkinsonian
phenotype. Interestingly, neuronal loss preferentially affected the
SNpc and other structures that reach maturation during early
postnatal life. Catecholaminergic nuclei, such as the locus coer-
uleus, that seem to be mature at birth were unaffected.
MATERIALS AND METHODS
Generation of the SDHD-ESR and TH-SDHD mouse strains. To obtain
both the inducible and tissue-specific SdhD mouse mutant strains, we
engineered a floxed allele, SdhDflox, which contains two LoxP sites flank-
ing exons 2 to 4 and a NEO cassette for cell selection (Fig. 1A). This
construct was targeted to the SdhD genomic locus by homologous recom-
bination in 129SvJ background R1 mouse embryonic stem (ES) cells.
Proper targeting was tested by Southern blotting of genomic DNA di-
gested with HindIII and hybridized against an external 5= probe (Fig. 1C).
To test the excision of the SdhDflox allele (Fig. 1B), targeted ES clones were
electroporated with a plasmid containing the CRE recombinase gene.
DNA from these cells was digested with EcoRV and analyzed by Southern
blotting (Fig. 1D) against a NEO probe. ES clones carrying the SdhDflox
allele were used for blastocyst injection and chimera generation. Germ
line transmission of the SdhDflox allele yielded heterozygous animals,
which were subsequently mated with SdhD/mice (40) carrying either
the tamoxifen-inducible CRE recombinase (20) or the Th-IRES-Cre
transgenes (29) to generate the experimental SDHD-ESR and TH-SDHD
mouse lines, respectively. Littermates with SdhDflox/ and SdhDflox/ ge-
notypes lacking CRE recombinase were used as control individuals. Un-
less otherwise specified, results from both control groups were pooled
since no differences between them was found for the phenotypes tested.
Routine genotyping was performed for the SdhD alleles by PCR with the
primers 5=-AATTGTGCAGAAGTGAG-3=, 5=-GCTGCATACGCTTGAT
C-3=, and 5=-CATCAAGGCTCACAGTC-3=.
Mouse husbandry and pharmacological treatments. Mice were
housed under temperature-controlled conditions (22°C) in a 12-h light/
12-h dark cycle and provided with food and water ad libitum. Either high
(100 g/g of body weight for 4 days) or low (50 g/g for 2 days) doses of
tamoxifen dissolved in corn oil were administered by daily i.p. injections.
The antioxidant tempol (Sigma) was given to pregnant females in drink-
ingwater protected from light at 2mM, starting 1 to 2 days before delivery
of pups and continuing until the sacrifice of littermates (day P15). All
experiments were performed in accordance with institutional guidelines
approved by the ethics committee of theHospital UniversitarioVirgen del
Rocio.
SdhD mRNA level. Adrenal medullas or striata were dissected and
stored frozen at80° until processing. Total RNA was prepared by using
an RNeasy microkit (Qiagen) according to themanufacturer’s directions.
Reverse transcription of mRNA was performed with a Superscript II re-
verse transcriptase kit (Invitrogen), and SdhD cDNA was amplified by
quantitative PCR with the primers 5=-CCAGCACATTCACCTGTCA-3=
and 5=-ATCAGCCCCAAGAGCAGAA-3= in the presence of SYBR green.
The Arbp housekeeping gene was used for normalization.
Mitochondrion isolation and mitochondrial complex II activity.
Mitochondria were isolated from mouse kidneys as reported elsewhere
(40). Succinate-ubiquinone oxireductase activity was determined as de-
scribed in reference 40, with slight modifications. Briefly, 30 to 50 g of
proteinwas assayed at 30°C. Samples were diluted 1:4 in the assay reaction
buffer (25mMKH2PO4 [pH7.2], 5mMMgCl2, 3mMpotassiumcyanide,
2.5 mg/ml bovine serum albumin) and freeze-thawed in liquid nitrogen
three times before the essay. Enzymatic activity wasmeasured for a period
of 2 min as the decrease in the absorbance at 600 nm due to the reduction
of 50 M 2,6-dichlorophenol-indophenol (DCPIP) coupled to reduc-
tion of 130 M ubiquinone-1. The reaction was carried out in the pres-
ence of 3.6 M antimycin, 5 M rotenone, and 10 mM succinate.
ATP level. Adrenal medullas were dissected and stored frozen at80°
until processing. For ATP determination, total extracts from thawed ad-
renal medullas were prepared by grinding them in 50 l of 100 mM Tris-
HCl, 4mMEDTAwith quartz sand and a plastic pestle followed by boiling
for 3min. After cooling on ice, samples were spun for 1min at 10,000 g.
Supernatant was collected for ATP determination with the ATP biolumi-
nescence kit HSII (Roche). Between 1 and 0.01g of protein was assayed,
as in this range the assaywas linear. Protein concentrationwas determined
by absorbance at 280 nm.
Oxidative damage. Mitochondrial DNA oxidative damage (44) and
lipid peroxidation (35) were determined according to published proto-
cols. Protein oxidation was analyzed with an OxyBlot protein oxidation
detection kit and an OxyIHC oxidative stress detection kit (Millipore),
according to manufacturer’s directions.
Tissue preparation and histochemistry. Histological analyses and
stereological cell counts were done by following previously described pro-
tocols (23, 32, 38). In brief, mice were anesthetized and killed by decapi-
tation.Dissected tissueswere fixed in paraformaldehyde and embedded in
OCT (Tissue-Tek), for carotid body and superior cervical ganglion, or
paraffin, for adrenal gland and brain, before sectioning. Peripheral tissue
sections 10 m thick were used for tyrosine hydroxylase (TH) immuno-
staining. Nuclei were detected by DAPI (4=,6=-diamidino-2-phenylin-
dole) staining. Coronal mouse brain sections 20 m thick were used for
tyrosine hydroxylase (TH), NeuN, parvalbumin, or DARP32 immuno-
staining. Antibodies and the dilution factors used were as follows: poly-
clonal antibody against TH (Novus Biologicals), 1:5,000; monoclonal an-
tibody against NeuN (Chemicon), 1:200; polyclonal antibody against
FIG 1 Generation of the TH-SDHDmutant mouse. (A) Scheme of the 16-kb
targeting construct engineered to contain two loxP sites (gray triangles) that
flank exons 2 to 4 (black boxes) of the SdhD gene, and a neomycin-resistance
(NEO) cassette for clone selection. This construct was targeted to thewild-type
SdhD genomic locus by homologous recombination. (B) CRE recombinase-
mediated excision of the SdhDflox allele. H, HindIII; E, EcoRV. Distances be-
tween relevant sites are indicated with dotted arrows. (C) Southern blot of
HindIII-digested DNA from neomycin-resistant ES clones, hybridized with a
probe against a 5= region. (D) Southern blot of EcoRV-digested DNA from
clones expressing the CRE recombinase, hybridized with a probe against the
NEO gene. Numbers on the left are band sizes, in kilobase pairs. The symbol
represents the excised SdhD allele. (E) Kaplan-Meier survival curves of control
and TH-SDHDmice.
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parvalbumin (Swant), 1:5,000; polyclonal antibody against DARP32
(Millipore), 1:5,000. For 3,3=-diaminobenzidine-based detection, an En-
vision kit (Dako) was used according to the manufacturer’s recom-
mended protocol. For fluorescence detection, Alexa-Fluor 568–anti-rab-
bit IgG was used. The size of the adrenal medulla was estimated with the
ImageJ software on photographs. In brain, unbiased stereological counts
of TH and NeuN immunoreactive neurons were performed in one of
every six brain sections covering the complete structure of interest by
using the CAST-Grid system coupled to an Olympus microscope with an
automated platform. The two hemispheres were considered.
In situ hybridization. Paraformaldehyde-fixed brains were embed-
ded in gelatin and sectioned in 50-m coronal slices with a vibratome.
Slices were incubated with a UTP-digoxigenin-labeled antisense RNA
probe obtained by T7 promoter-driven transcription of an SdhD cDNA
containing plasmid (IntegratedMolecular Analysis ofGenomes andTheir
Expression Consortium [IMAGE] clone 3989833) overnight at 57°C. Af-
ter extensive washing, slices were incubated with an antidigoxigenin an-
tibody conjugatedwith alkaline phosphatase (Roche) in a 1:1,000 dilution
overnight at 4°C, followed by incubation in 6l/ml nitroblue tetrazolium
(NBT) and 4.6 l/ml 5-bromo-4-chloro-3-indolylphosphate (BCIP)
(Roche) for 7 h at room temperature for detection.
X-Gal staining and confocal microscopy. Expression of CRE recom-
binase in catecholaminergic tissues of the TH-SDHD mouse was evalu-
ated by mating these mice with floxed Rosa26-lacZ (R26R) mice (52).
5-Bromo-4-chloro-3-indolyl--D-galactopyranoside (X-Gal) staining
was done as reported before (37, 56). Images of TH-immunostained sec-
tions containing X-Gal-stained precipitates were acquired with a TCS SP2
Leica confocal microscope. Lateral projection images were generated
from stacks of optical sections spaced 0.8 m apart using the Leica soft-
ware package.
HPLC. Striata were dissected from brains in ice-cold phosphate-buff-
ered saline (PBS) and sonicated on ice. Homogenates were filtered by
Ultrafree-MC centrifuge filter units (Millipore) and kept at 80°C until
use. For high-pressure liquid chromatography (HPLC) analysis of dopa-
mine and related metabolites, samples were passed through a chromato-
graphic ALB-215 column (ANTECLeyden) according to themanufactur-
er’s directions.
Open field tests. To assess the motor dysfunction phenotype, mice
were subjected to an open-field test in a 22.5-cm by 22.5-cm arena for 1 h.
Individual animals were monitored using an automatic tracking system
(SMART, Panlab). Traveled distance and resting time parameters were
calculated using the SMART software (version 2.5.14) (38).
Statistical analysis. Data are presented as means standard errors of
the means (SEM). Statistical significance was assessed by Student’s t test
with a Levene test for homogeneity of variances, in cases of normal distri-
bution, or by the nonparametric Mann-Whitney U test, in cases of non-
normal distribution. PASW18 software was use for statistical analysis.
RESULTS
Survival of SdhD-deficient mice and loss of peripheral cat-
echolaminergic cells. Heterozygous SdhDflox/ animals with
complete germ line ablation of SdhD in catecholaminergic cells
(TH-SDHDmice) appeared healthy at birth, and although smaller
than their littermates, they seemed to develop normally during the
first postnatal months. However, most mutant mice died before
the end of the first year of life (Fig. 1E), probably due to the pro-
gressive and extensive cell loss occurring in some catecholaminer-
gic organs and brain nuclei (see below).
TH-SDHDmice, even those that survived for up to 1 year, did
not show any indication of tumor transformation in the periph-
eral catecholaminergic tissues. On the contrary, quantitative his-
tological analyses showed amarked decrease of catecholaminergic
cells. We studied in detail the adrenal medulla (AM), a relatively
large organ almost exclusively formed by compacted strands of
chromaffin cells that allowed us to carry out biochemical analyses.
AM volume was approximately similar in newborn wild-type and
SdhD-deficient animals; however, maturation and growth of the
chromaffin tissue during the first postnatal weeks were markedly
altered in TH-SDHDmice (Fig. 2A and B). AM cells also showed
a significant decrease of intracellular ATP content, indicating an
alteration of ETC (Fig. 2C). We used several methods (see Mate-
rials andMethods) to ascertainwhether SdhD deletion induced an
oxidative stress in the surviving AM tissue, with inconclusive re-
sults. However, we did see some evidence of selective increase of
lipid peroxidation in chromaffin cells of mutant animals (Fig.
2D). Like the AM, other TH structures, such as the carotid body
(CB) and neighboring superior cervical ganglion (SCG), of juve-
nile animals also presented a clear decrease in the number of cat-
echolaminergic cells (Fig. 2E to H).
As it could be possible that complete maturation of the cat-
echolaminergic organs is a prerequisite for tumor induction after
SdhD deletion, we also generated a time-inducible SdhD mutant
model by breeding the SdhD floxed mouse line with a strain con-
taining a tamoxifen-inducible CRE (20). These animals (desig-
nated SDHD-ESR mice) carried a paternally inherited SdhD-null
allele and a maternal SdhD floxed allele to be excised after CRE
activation, thus mimicking the human scenario for familiar para-
ganglioma. Measurement of SdhD mRNA levels in adrenal me-
dulla and kidney soon after tamoxifen treatment confirmed dele-
tion of the maternally inherited SdhD allele in adult mutant mice
(Fig. 3A). In accord with these data, a parallel decrease of succi-
nate-ubiquinone oxireductase activity was measured in isolated
kidney mitochondria (Fig. 3B). Analyses of AM and CB in the
SDHD-ESR strain performed before the death of themice (occur-
ring	3weeks after tamoxifen treatment) indicated the absence of
tumorigenesis in these organs and a clear trend toward degenera-
tion of the carotid body (Fig. 3C and D). SDHD-ESR animals
treated with lower doses of tamoxifen (see Materials and Meth-
ods) survived longer (	8 to 9 weeks) but showed no signs of
tumor transformation or hypertrophy in either the AM or CB
(data not shown).
Impaired SNpc postnatal maturation and maintenance in
TH-SDHD mice. In parallel with the catecholaminergic cell loss in
the peripheral nervous system, TH-SDHD animals showed a
marked and progressive postnatal reduction in the number of
ventral mesencephalic TH neurons (Fig. 4A). Vulnerability of
dopaminergic neurons of the substantia nigra pars compacta
(SNpc) and ventral tegmental area (VTA) to mitochondrial SdhD
deficiency was evaluated by comparative cell count analyses in
control and in TH-SDHDmice during the first year of life (Fig. 4B
to D). Although neonatal animals already had a small population
of TH ventral mesencephalic cells, most SNpc and approxi-
mately half of VTA dopaminergic neurons in normal mice ac-
quired their postmitotic TH phenotype during the first postnatal
month, and after reaching a maximum, their number remained
constant in adulthood (9, 26). This pattern of ontogenic develop-
ment was altered in TH-SDHD animals. These mice were born
with a slight, nonsignificant decrease of TH cell number in the
SNpc and similar cell number in VTA in comparison with their
respective controls but showed a characteristic inhibition of post-
natal neuronmaturation and progressive death of TH cells upon
reaching adulthood. These processes, impaired maturation and
accelerated degeneration of dopaminergic cells, were quite aggres-
sive in the SNpc, resulting in an almost total disappearance of
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TH cells in this structure between 6 and 12months of animal age
(Fig. 4B). In the same period, 	30% of TH cells in VTA re-
mained (Fig. 4C). These observations indicate that, similar to
what occurs in PD patients (14, 15), SNpc neurons are far more
sensitive tomitochondrial dysfunction thanVTA. Staining of ven-
tral mesencephalic neurons withNeuN, a panneuronalmarker, in
3.5-month-old animals further demonstrated the differential
neuronal death in the SNpc and VTA of TH-SDHD mice rather
than a loss of TH expression (Fig. 4D). Themolecular mechanism
of dopaminergic mesencephalic neuronal death in the TH-SDHD
mice is unknown, as we could not demonstrate any indication of
either caspase-3 activation or nucleus fragmentation in tissue
samples from these animals.
Ablation of the SdhD gene in catecholaminergic cells of the
TH-SDHD mouse is expected to increase the production of ROS
in mitochondria, as mutations in Sdh proteins have been demon-
strated to increase oxidative stress in both in vivo and in vitro
systems (19, 25). In accord with this concept, we also observed an
increase of lipid peroxidation in AM tissue from TH-SDHD ani-
mals (Fig. 2D). Hence, we tested the effect of the superoxide dis-
mutase mimetic tempol (57) upon the postnatal maturation of
SNpc neurons. To this end, we added the antioxidant to the drink-
ingwater at late stages of gestation and until sacrifice of littermates
15 days after birth. Tempol induced a 48% increase in the number
of TH SNpc neurons in TH-SDHD animals (4,998  261 neu-
rons in treated mice versus 3,370  486 neurons in nontreated
animals [mean  SEM]; n 
 7 and 4, respectively; P 
 0.01).
However, the effect of tempol in control animals was smaller
(13%) and nonsignificant (8,740  647 neurons in treated mice
versus 7,743 349 in nontreated mice; n
 5; P
 0.21).
Brain catecholaminergic neurons matured at birth were un-
affected by SdhD ablation. The analysis of catecholaminergic cell
death in the TH-SDHDmouse was extended to brainstem nuclei,
such as the noradrenergic locus coeruleus (LC) or the dopaminer-
gic group A13, in whichmost of the neurons had already acquired
the catecholaminergic phenotype at birth. In contrast with the
accentuated neuronal loss seen in the SNpc, and to a lesser extent
in VTA, of TH-SDHD animals, neuron numbers in LC and group
A13 were unaltered by the mutation during the first year of life
(Fig. 5). As no antibodies for SdhD protein immunodetection are
available, we attempted in situ histochemical determination of
succinate-ubiquinone oxireductase activity in brain sections. This
technique did not provide conclusive results, probably because
affected neurons (without oxireductase activity) were intermin-
gled with unaffected cells.
Therefore, to confirm that CRE-mediated recombination had
FIG 2 Histological analyses of peripheral catecholaminergic organs of control and TH-SDHDmice. (A) Representative photographs of adrenal glands fromP75
mice. (B) Postnatal increase of volume of the adrenal medulla. (C) ATP levels in adrenal medulla of P75 to P105mice. (D) Lipid peroxidation in AMof P75mice
for both separate controls (flox/ and flox/- without CRE) and mutant groups. Similar analysis performed in liver tissue showed no difference between control
and TH-SDHD mice (data not shown). (E and F) Representative photographs and numbers of TH cells in carotid bodies (CB) from P75 mice. (G and H)
Representative photographs and density of TH cells in superior cervical ganglion (SCG) from P75 mice. All tissues were immunostained for tyrosine hydrox-
ylase (TH, red). Nuclei were stained with DAPI dye. AG, adrenal gland; AM, adrenal medulla; ca, carotid artery. Bars, 100m (E) and 200m (A and G). There
were 4 to 8 individuals per group and age. *, P 0.05; **: P 0.01; ***, P 0.001 (control versus TH-SDHD groups).
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taken place in the unaffected LC and A13 neurons, we checked the
expression of functional CRE recombinase, as well as the deletion
of the SdhDflox allele in the TH neurons of these regions. To this
end, we generated a TH-SDHD/R26R mouse line (see Materials
and Methods) in which we demonstrated colocalization in every
TH neuron of X-Gal staining (indicative of CRE recombinase-
dependent DNA deletion at the floxed R26R locus) with TH im-
munoreactivity in brain sections, including LC and A13 nuclei
(Fig. 6A). In addition, in situ hybridization analyses directly indi-
cated that SdhDmRNAexpressionwas abolished in LCneurons of
TH-SDHDmice to an extent similar to that seen in dopaminergic
SNpc or VTA cells, whereas SdhD mRNA expression remained
unaltered in noncatecholaminergic cells (Fig. 6B). LC neurons
seem to have an extraordinary resistance to mitochondrial com-
plex II dysfunction, as both CRE mediated R26R expression and
SdhD ablation (as determined by in situ hybridization analysis)
were tested to occur in LC neurons of juvenile TH-SDHD animals
(one month old or younger). In contrast, LC TH neuron num-
bers remained unaltered in 1-year old mutants (Fig. 5C). Alto-
gether, these data unequivocally demonstrate that SNpc neurons
have special sensitivity to genetic mitochondrial SdhD inhibition
in comparison with cells in other catecholaminergic nuclei.
Previous studies with the Th-IRES-Cre mouse (29) suggested
that transient TH activation may occur during development in
areas that are not TH in adults. In our TH-SDHD/R26R animals,
we observed a very low level of R26R expression in the striatum,
cortex, and hippocampus compared with the SNpc and other
TH structures. As expected, all the noncatecholaminergic brain
areas studied (particularly the cerebral cortex and hippocampus)
were normal in TH-SDHDmice (data not shown). In addition, we
also checked that the number of DARP32 medium spiny neu-
rons, the most numerous in the striatum, was normal in TH-
SDHD mice (Fig. 7A). Moreover, the number of parvalbumin-
positive GABAergic interneurons, which provide most of the
neurotropic support for dopaminergic nigrostriatal neurons (23),
was also unaffected by SdhD ablation (Fig. 7B). Finally, a quanti-
tative analysis of the level of SdhDmRNA expression in the stria-
tum showed that CRE recombinase-dependent SdhD deletionwas
not aberrantly activated in noncatecholaminergic striatal cells of
TH-SDHD animals (Fig. 7C). Together, these data make it un-
likely that CRE expression during development in regions other
than the TH catecholaminergic areas makes any major contri-
bution to the histological and functional phenotype of TH-SDHD
animals.
Progressive parkinsonian phenotype in TH-SDHD mice. As
a consequence of the loss of dopaminergicmesencephalic neurons
FIG 3 Lack of carotid body hypertrophy in SDHD-ESR mice. (A) Levels of SdhD mRNA in kidney and adrenal gland of separate control (flox/ and flox/
without CRE) groups and mutant individuals 5 days after tamoxifen injection (at P50), demonstrating general loss of SdhD. r. u., relative units. There were 3 to
7 individuals per group. (B) Succinate ubiquinone oxireductase activity (MCII) in mitochondria isolated from kidney cells 3 weeks after tamoxifen injection.
There were 3 to 6 individuals per group. (C) Carotid body (CB) immunostained for tyrosine hydroxylase (TH) 3 weeks after tamoxifen injection. Bar, 100 m.
(D) Total and TH fraction volumes of carotid bodies from control (n
 3) and SDHD-ESR (n
 4) animals 3 weeks after tamoxifen injection (at P50). *, P
0.05; ***, P 0.001.
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projecting to the striatum, TH-SDHD animals exhibited intense
striatal dopaminergic denervation, which seemed to be almost
complete at 2 to 3months of age (Fig. 8A).Measurement of striatal
dopamine and its degradation metabolites indicated a profound
neurochemical defect in SdhD-deficient animals. In normal mice,
a postnatal increase in the number of TH neurons of the SNpc
resulted inmaturation of the nigrostriatal pathway, with amarked
rise in the caudate putamen content of dopamine as well as in
3,4-dihydroxyphenylacetic (DOPAC) and homovanillic acid
(HVA) levels. The postnatal increases of dopamine and its metab-
olites were almost abolished in striata from 2.5-month-old TH-
SDHD animals (Fig. 8B). Striatal denervation in mutant animals
seemed to be complete in 2.5-month-old animals, even though a
significant number of SNpc andVTAneurons remained alive (Fig.
4A to C). This suggests that in TH-SDHD mice, the nigrostriatal
pathway does not reach full mature development and that the loss
of dopaminergic axon terminals could precede death of SdhD/
neurons. As indicated above, striatal parvalbumin-positive cells,
which provide most of the glial-cell-line-derived neurotropic fac-
tor (GDNF) needed for trophic maintenance of nigrostriatal neu-
rons (23, 38), were unaltered in TH-SDHDmice (Fig. 7B), ruling
out possible noncell autonomous effects of SdhD ablation on do-
paminergic nigrostriatal neurons.
We also studied whether the anatomical and neurochemical
nigrostriatal defects in TH-SDHD animals correlate with a behav-
ioral phenotype by performing open-field tests at different ages.
TH-SDHD mice showed a progressive bradykinetic syndrome
characterized by marked decrease in the distance traveled in the
open field and increase in time spent at rest (Fig. 8C and D).
DISCUSSION
In this paper we describe a new conditionalmousemodel of SdhD
deficiency, which was designed to study tumorigenesis in para-
ganglionic cells as well as to compare the vulnerability of periph-
eral and central catecholaminergic neurons to primarymitochon-
drial ETC dysfunction. In humans, SDHD is considered a tumor
suppressor gene, because loss-of-functionmutations are the cause
of some hereditary paragangliomas, mainly affecting the carotid
body (3, 6). Individuals carrying the mutation are heterozygous,
and loss of the normal allele in the affected cells (LOH) is required
for tumor transformation (5, 6, 22). SdhD/mice are nonviable,
and heterozygous SdhD/ animals fail to develop tumors, sug-
gesting that spontaneous LOH of this locus does not take place in
mouse paraganglia (4, 40). In our TH-SDHD mice, we achieved
complete deletion of both SdhD alleles in TH cells, a condition
postulated to be the initiating event for tumor transformation.
FIG 4 Loss of ventral mesencephalic dopaminergic neurons in TH-SDHD mice. (A) TH immunostaining of neurons in the SNpc and VTA of control and
TH-SDHDmice at postnatal days (P) 0, 30 and 180. Bar, 200 m. (Insets) Neurons at a higher magnification (2.5 the main figure). Number of TH neurons
in the SNpc (B) andVTA (C) at different animal ages. (D)NeuN cell number in the SNpc andVTA of P105mice. There were 3 to 8 individuals per point. *, P
0.05; **, P 0.01; ***, P 0.001 (control versus TH-SDHD groups). #, P 0.05; ##, P 0.001 (P30 versus subsequent ages).
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However, far from developing tumors, these animals underwent
loss of catecholaminergic cells in the peripheral nervous system.
Although TH-SDHD animals had a shortened life span, likely
caused by extensive central and peripheral catecholaminergic cell
loss, examination of animals that survived even for 1 year never
resulted in the detection of tumors.
Genetic andmolecular studies have demonstrated that the inher-
ited pattern of paraganglioma involves a parent-of-origin effect (6,
34), which indicates some form of genomic imprinting. Further-
more, it has been suggested that loss of a second imprinted locus in
the same chromosome of SdhD is necessary for paraganglioma for-
mation (22). In this regard, a heterozygousmutantwithmutations in
both SdhD and H19, another imprinted locus proposed to be in-
volved in hereditary paraganglioma, also failed to show any propen-
sity for tumorigenesis (4). It could also be possible that complete
maturationof theAMandCB is aprerequisite for tumor appearance.
However, heterozygous SdhDflox/ animals, inwhichwe induced loss
of the maternally inherited SdhD allele in adulthood (SDHD-ESR
mice), also failed to show any tumoral or hypertrophic phenotype.
The fact that both the TH-SDHD and SDHD-ESRmice, despite be-
ing subjected to loss of the two copies of the gene in catecholaminer-
gic tissues, didnotdisplay tumor features further strengthens the idea
that a “second hit” is required for paraganglioma pathogenesis. Dif-
ferences in chromosomal arrangements between humans and
mouse, or unknown distinct biochemical features between the two
species, could account for the resistance to development of paragan-
glioma/pheochromocytoma inmouse.
As indicated above, SdhD deficient mice have also been used as
a model of mitochondriopathy to investigate the effect of primary
mitochondrial ETC inhibition on postnatal maturation of SNpc
dopaminergic neurons as well as their maintenance in adult life in
comparison with other catecholaminergic cells. Although a vast
amount of literature suggests thatmitochondria play a central role
in PD pathogenesis (14, 39, 47, 48), whether dopaminergic SNpc
neurons, the cell group whose destruction is responsible for most
of the motor symptoms in PD, are especially susceptible to mito-
chondrial dysfunction is not definitely established. Surprisingly,
there has also been little investigation of whether mitochondrial
deficiencies alter the ontogenic maturation of ventral mesen-
cephalic neurons, an elaborate sequence of events occurring dur-
ing the early postnatal period that involves programmed cell death
and acquisition of the dopaminergic phenotype, thus determining
the number of TH SNpc neurons that reach adulthood (9, 26).
Systemic application of toxins, like MPTP or rotenone, which
inhibit mitochondrial complex I has been reported to induce a
rather selective dopaminergic SNpc cell loss (7, 28; for reviews, see
references 14 and 39). These actions havemostly been observed in
adult animals, although previous studies described alterations of
adult mesencephalic dopaminergic neurons after application of
low doses ofMPTP and othermitochondrial inhibitors during the
FIG 5 (A and B) TH immunostaining of noradrenergic neurons in the locus coeruleus (A) and dopaminergic nucleus A13 of the zona incerta (B) of control and
TH-SDHDmice at postnatal day 180. (Insets) Neurons at higher magnification (3 the main figure). The axonal bundle of the nigrostriatal pathway (NSP) is
shown. Bar, 200 m. (C and D) Numbers of TH neurons in LC (C) and A13 (D) at different ages. There were 3 to 8 individuals per point.
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neonatal period (17). A differential protective response of micro-
glia toMPTP treatment between neonatal and adult mice has also
been reported (45). However, the effects of systemic toxins de-
pend largely on their distribution and uptake by the different cel-
lular types in the brain and therefore do not unequivocally reflect
an inherent sensitivity of the affected neurons to mitochondrial
poisoning. Within the context of this discussion, it may be also
worth considering that rotenone, a lipophilic substance, can block
K currents in several cell types (1, 30, 50) and alter global oxygen
homeostasis by interfering with carotid body oxygen sensing (36).
On the other hand, several genes mutated in familial forms of PD
have been shown to encode proteins located in, or capable of in-
teracting with, mitochondria (49, 55). Deletion of these genes
does not induce SNpc cell death in mice (27), thus casting doubts
onwhethermitochondrial bioenergetics alterations per se can lead
to neurodegeneration. It has previously been reported that genetic
ablation of mitochondrial DNA-encoded genes causing alteration
in the function of complexes I, III, IV, and V results in extensive
death of ventral mesencephalic dopaminergic neurons. Nonethe-
less, the selective effect of this mitochondrial damage on SNpc
cells, in comparison with other neuronal types, has not been stud-
ied in detail (16). In this report we show that mitochondrial dys-
function in mice restricted to catecholaminergic brain areas
causes a major inhibition of postnatal mesencephalic dopaminer-
gic neuron phenotypic specification, thus causing a progressive
PD-like syndrome due to cell loss predominantly affecting the
SNpc. Other catecholaminergic neuronal groups, such as the do-
paminergic A13 and noradrenergic LC, that were already mature
at birth were practically unaltered. Therefore, these data indicate
that SNpc neurons are highly vulnerable to mitochondrial dys-
function. Death of dopaminergic nigrostriatal neurons in TH-
SDHD mice appeared to be a cell-autonomous phenomenon,
since these mutant animals did not show abnormalities in other
areas of the brain or in the striatal neurons innervated by the
dopaminergic terminals.
We have shown that in adrenal chromaffin cells, SdhD ablation
leads to a decrease in ATP content. Therefore, the cell loss, partic-
ularly in the dopaminergic SNpc cell group, observed in the TH-
SDHD mice could be a consequence of bioenergetic deficiency,
possibly aggravated by mitochondria ROS overproduction due to
inefficient transference of electrons from Sdh to ubiquinone, sim-
ilar to what occurs in cells lacking SdhB or SdhC proteins (19, 25).
The involvement of mitochondrial ROS in SNpc cell damage was
proposed several years ago (46), and a causative link between ROS
production and selective SNpc cell loss was recently established.
Adult dopaminergic SNpc neurons are autonomous Ca2-depen-
dent pacemakers that require a proper mitochondrial ETC func-
tion for cytosolic Ca2-buffering homeostasis. Therefore, these
cells are normally exposed to an oxidant stress, derived from the
particularly active ETC, which not only compromises their long-
FIG 6 (A) Confocal microscope photographs of the locus coeruleus and do-
paminergic nucleus A13 showing colocalization of X-Gal (blue dots) and TH
(red) neurons in a TH-SDHD mouse carrying the R26R reporter construct.
(B) In situ hybridization of SdhDmRNA in the hippocampus, SNpc-VTA, and
LC.Note the complete disappearance ofmRNA in the catecholaminergic areas
(encircled by dotted lines) of the TH-SDHDmouse. Note also that the level of
SdhDmRNA expression in the hippocampus of control animals (homozygous
for SdhD)was higher than in heterozygousTH-SDHDmice (40). Bars, 500m
(hippocampus), 200 m (SNpc/VTA), and 100 m (LC).
FIG 7 Lack of striatal affects in the TH-SDHD mouse. (A and B) Number of
DARP32-positive (A) and parvalbumin-positive (B) neurons in the striata of
control and TH-SDHD mice at P75. Immunostaining of striatal neurons was
done as described in reference 23. Cell counts were done in 20-m-thick slices.
Therewere 3 individuals per group. (C) SdhDmRNA levels in striata of control
and TH-SDHD mice at P30, as determined by RT-qPCR of total RNA. r. u.,
relative units. There were 3 to 4 individuals per group. **, P 0.01 for control
versus TH-SDHD groups.
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term survival but also makes them particularly vulnerable to mi-
tochondrial alterations (11, 18). In accord with this idea, systemic
antioxidant treatment of TH-SDHD mice with tempol appeared
to have a protective role with regard to SNpc neurons and favored
catecholaminergic phenotypic specification. However, this obser-
vation must be taken as preliminary, since although we have been
able tomeasure a higher level of lipid peroxidation in AM samples
fromTH-SDHDmice compared to controls, other signs of oxida-
tive stress, such as oxidative DNA damage or increased protein
oxidation, were undetectable. In addition, due to technical limi-
tations, we do not have yet any direct measurement of ROS levels
in SNpc neurons of themutant animals. Nevertheless, it is intrigu-
ing that other catecholaminergic cells, for example, those in the
LC that, like SNpc neurons, posses large terminal axonal fields and
exhibit Ca2-dependent spontaneous action potential firing (10),
are resistant to mitochondrial dysfunction. Although Ca2-de-
pendent pacemaking is surely amajor risk for neurodegeneration,
our findings suggest that additional metabolic and/or develop-
mental differences between SNpc and other catecholaminergic
neurons must exist to explain their distinct sensitivity to mito-
chondrial ETC inhibition. It is known that adult SNpc and LC
neurons are both highly sensitive to glial-cell-line-derived neu-
rotropic factor (GDNF) deficiency (38), and this trophic factor
protects LC neurons against oxidants (2). Therefore, it could be
that in TH-SDHD animals, LC neurons are unaffected because
they have stronger trophic support and antioxidant defense than
SNpc cells. Indeed, a peculiar property of SNpc neurons with re-
spect to LC and A13 cells is that the former reach full phenotype
specification in postnatal life, which includes TH expression as
well as final establishment of synapses at the distant striatum (9).
In addition, we have recently shown that GDNF expression by
neostriatal interneurons, necessary to support trophically SNpc
cells, is not yet fully developed at birth but matures during post-
natal weeks 2 to 4 (23). Neurons of LC or A13, which mature
during embryonic life, may have reached some of their targets at
birth and therefore are provided with the trophic support that
endows them with resistance to Sdh deficiency. In contrast, the
postnatal development of the nigrostriatal pathway and striatal
GDNF-producing interneurons leaves SNpc cells deprived of tar-
get-derived trophic support for a period during which they are
more susceptible to mitochondrial dysfunction. It is likely that in
TH-SDHD animals, the nigrostriatal pathway never reaches full
maturation. This would explain why they have complete striatal
denervation even at early juvenile stages, despite the fact that nu-
merous SNpc TH cells are conserved. Lack of trophic support
during postnatal maturation and strict dependence onmitochon-
drial ETC function are features that together could explain the
exceptional vulnerability of the SNpc to stressful conditions.
The data presented here provide unequivocal support for a
major selective role of mitochondria in SNpc neuronal loss in PD;
however, it must be noted that TH-SDHD mice do not exactly
reproduce the neuronal loss seen in PD. For example, TH-SDHD
animals had a clear loss of dopaminergic neurons in the VTA,
whereas these neurons are spared or only slightly affected in PD
patients as well as in theMPTPmousemodel of PD. Furthermore,
LC neurons, unaltered in TH-SDHD animals, are also affected in
PD. The observations in this report reinforce a relatively little
explored perspective in PD pathogenesis associated with early
postnatal SNpc cell phenotypic specification, which could also be
strictly dependent on proper mitochondrial function. In this re-
FIG 8 Parkinsonian phenotype of TH-SDHD mice. (A) TH immunostaining of striata of control and TH-SDHD mice at P75. Bar, 500 m. CPu, caudate
putamen; Acb, accumbens nucleus. (B) Dopamine (DA), 3,4-dihydroxyphenylacetic (DOPAC), and homovanillic acid (HVA) levels in striatum at P75, as
determined byHPLC. Therewere 3 to 8 individuals per point. (C)Walking traces of control andTH-SDHDmice in an open-field test for 1 h at the indicated ages.
(D) Quantification of distance traveled and resting time (RT). There were 3 to 6 individuals per point. **, P 0.01; ***, P 0.001 (control versus TH-SDHD
groups); ##, P 0.001 for P40 versus later ages.
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gard it is worth emphasizing that TH-SDHD mice show death in
peripheral sympathetic neurons and paraneurons, as is also ob-
served in early stages of PD (33, 54). Our results support the long-
standing notion (17) that subtle developmental alterations or expo-
sure to environmental pollutants, occurring during the critical
perinatal period, could diminish the final number of physiologically
mature SNpc neurons. In accord with the proposed “multiple-hit”
hypotheses for PD (13, 53), the affected individuals would surely be
more susceptible to other hits damaging SNpc neurons later in life,
thus predisposing them to suffer the disease in adulthood.
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